$UNCY News

Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $18

Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside

Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $37

Unicycive Therapeutics Q1 EPS $(0.54) Misses $(0.51) Estimate

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $15

Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $40

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Unicycive Therapeutics Q4 EPS $(0.82) Misses $0.03 Estimate

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit

Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics Issues Update, States PDUFA Target Action Date Now June 29, 2026, For Oxylanthanum Carbonate FDA New Drug Application

Unicycive Therapeutics Issues Update, States PDUFA Target Action Date Now June 29, 2026, For Oxylanthanum Carbonate FDA New Drug Application

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

The FDA Has Accepted Resubmission Of Unicycive Therapeutics' New Drug Application For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth

Unicycive Therapeutics Has Resubmitted Its 505(b)(2) New Drug Application To FDA For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis